NextCell Pharma Reports Third Quarter 2025 Earnings

NextCell Pharma (STO:NXTCL) Third Quarter 2025 Results

Key Financial Results

• Revenue: kr2.26m (down 8.9% from 3Q 2024).
• Net loss: kr10.3m (loss widened by 16% from 3Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

NextCell Pharma Earnings Insights

Looking ahead, revenue is forecast to grow 142% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 21% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with NextCell Pharma (at least 3 which are potentially serious), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.